TSX Exchange Symbol: RVX
CALGARY, Feb. 11, 2014 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) announced today that Arthur Higgins will be stepping down from the Board of Directors after fulfilling his commitment in helping Resverlogix spin out Zenith Epigenetics. Resverlogix's management and Board of Directors would like to thank Arthur for his commitment and positive input during this time.
Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company developing compounds involving ApoA-I production. RVX-208 is a first-in-class small molecule in development for the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and our IR App found on Apple products iTunes and Android users (Google Play).
SOURCE Resverlogix Corp.